NCT04239157View on ClinicalTrials.gov

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
Interventions
BIOLOGICAL

Canakinumab

Given SC

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER